Cellectar Biosciences
CLRB
38 hedge funds and large institutions have $6.77M invested in Cellectar Biosciences in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 12 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0.04% less ownership
Funds ownership: 0.08% → 0.04% (-0.04%)
12% less funds holding
Funds holding: 43 → 38 (-5)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
54% less capital invested
Capital invested by funds: $14.9M → $6.77M (-$8.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$457K |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$367K |
| 3 |
Franklin Resources
San Mateo,
California
|
+$145K |
| 4 |
Bank of New York Mellon
New York
|
+$94.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$4.66M |
| 2 |
Renaissance Technologies
New York
|
-$574K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$508K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$354K |
| 5 |
Two Sigma Advisers
New York
|
-$296K |
CLRB Hedge Fund Activity: Q3 2021 in Review
38 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2021, worth a combined $6.77M — down 54% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CLRB and 8 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Morgan Stanley, adding an estimated $457K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $4.66M sold.
- 38 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2021, down from 43 in Q2 2021.
- Funds reported $6.77M of Cellectar Biosciences stock for Q3 2021, down 54% quarter-over-quarter.
- 8 funds opened new Cellectar Biosciences positions in Q3 2021 and 12 closed out, a net change of -4 holders.
- The largest Cellectar Biosciences buyer in Q3 2021 was Morgan Stanley, an estimated $457K added.
- The largest Cellectar Biosciences seller in Q3 2021 was Consonance Capital Management, an estimated $4.66M sold.
Based on aggregated 13F filings for Q3 2021.